2018
DOI: 10.1007/s00011-018-1185-0
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In spite of prosperous experiences in MS therapy, the future research, hopefully, will bring substantial improvements in the understanding and approaches of MS therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
69
0
8

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 108 publications
(77 citation statements)
references
References 134 publications
0
69
0
8
Order By: Relevance
“…Numerous studies have revealed activation and recruitment of autoaggressive CD4 + and CD8 + T cells into the CNS as the main pathogenic players of MS (59,60). Disease-modifying treatments (DMTs) especially IFN-β are commonly prescribed to treat the affected individuals (61,62). Despite their beneficial impacts, DMTs increase the risk of adverse effects including lymphopenia, lymphadenopathy, dyspnea and lipoatrophy (63)(64)(65).…”
Section: Multiple Sclerosismentioning
confidence: 99%
“…Numerous studies have revealed activation and recruitment of autoaggressive CD4 + and CD8 + T cells into the CNS as the main pathogenic players of MS (59,60). Disease-modifying treatments (DMTs) especially IFN-β are commonly prescribed to treat the affected individuals (61,62). Despite their beneficial impacts, DMTs increase the risk of adverse effects including lymphopenia, lymphadenopathy, dyspnea and lipoatrophy (63)(64)(65).…”
Section: Multiple Sclerosismentioning
confidence: 99%
“…Currently, there is no definitive treatment for multiple sclerosis. Most approved therapies are focused on controlling peripheral inflammation and preventing migration across the blood brain barrier thereby reducing the incidence of acute flares [13,30,39,40]. A majority of these therapies are administered orally, as an injection or through an infusion.…”
Section: Current Disease-modifying Therapiesmentioning
confidence: 99%
“…A majority of these therapies are administered orally, as an injection or through an infusion. With both invasive and non-invasive methods, side effects include increases in liver enzymes, injection site reactions, nausea, diarrhea, and most importantly, progressive multifocal leukoencephalopathy (PML) [39]. The primary therapies prescribed at our institution are Copaxone ® , Gilenya ® , and Tecfidera ® .…”
Section: Current Disease-modifying Therapiesmentioning
confidence: 99%
“…This is called remyelinating therapy. 5 There is also interest in developing treatments that keep injured nerve cells from degenerating. Such therapies are referred to as being neuroprotective.…”
Section: How Is Ms Treated?mentioning
confidence: 99%